KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Shangzhu Zhang, Dong Xu, Shengyun Liu, Shujie Li, Xiaoxia Wang, Fenghong Yuan, Wei Gou, Baijie Xu, Lingyun Sun, Jieruo Gu, Dongmei Zhou, Xiaomei Li, Ning Kong, Yi Zhao, Jie Hao, Tianwang Li, Xiaoyun Fan, Qiang Shu, Hua Wei, Tao Jiang, Jing Yang, Long Qian, Hongsheng Sun, Xiaoyan Cai, Zhenyu Jiang, Guohua Yuan, Li Qin, Min Yang, Jian Xu, Wenqiang Fan, Li Sun, Hua Zhang, Chunyan Zhang, Ning Zhang, Zhanyun Da, Jiankang Hu, Jingchun Jin, Ju Liu, Lie Dai, Lingli Dong, Wei Wang, Xiaofeng Zeng

BioDrugs 40(1) 151-162

PMID41247398
PMCIDPMC12790509
DOI10.1007/s40259-025-00750-0
发表日期2025-11-17
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。
摘要

摘要

BACKGROUND: Xeligekimab is a novel immunoglobulin G4 (IgG4) monoclonal antibody targeting interleukin-17A (IL-17A). In a phase III trial in patients with plaque psoriasis, xeligekimab showed efficacy and safety consistent with other IL-17A inhibitors, supporting its potential application in the treatment of spondyloarthritis. OBJECTIVE: This phase III trial aimed to investigate the efficacy and safety of xeligekimab in patients with radiographic axial spondyloarthritis (r-axSpA). METHODS: This was a phase III study conducted at multiple centers in China. Eligible patients were randomly assigned (1:1:1) to receive xeligekimab 100 mg, xeligekimab 200 mg, or placebo. Randomization was stratified by medication history (biologic-experienced vs. biologic-naïve) and weight (≥ 70 kg vs. < 70 kg). The primary endpoint was the proportion of patients achieving an Assessment of SpondyloArthritis International Society 20 (ASAS20) response at week 16. A key secondary endpoint was the ASAS40 response rate at the same time point. RESULTS: A total of 465 patients were recruited. A significantly higher proportion of patients receiving xeligekimab 200 mg (n = 114 (74.0%); p < 0.001, 95% confidence interval (CI) 28.5-48.4) and xeligekimab 100 mg (n = 102 (65.8%); p < 0.001, 95% CI 19.4-41.0) achieved an ASAS20 response compared to the placebo group (n = 56 (35.9%)) at week 16. Similarly, a significantly higher ASAS40 response rate was observed in the xeligekimab 100 mg group (n = 62 (40.0%); p < 0.001) and the xeligekimab 200 mg group (n = 64 (41.6%); p < 0.001) compared to placebo. Adverse events were similar across all groups, with serious adverse events occurring in 1.6% of the treatment group during the core treatment period. No unexpected safety signals were reported through week 48. CONCLUSION: Xeligekimab demonstrated significant efficacy in improving the signs and symptoms of active r-axSpA in Chinese patients at week 16, with sustained effects observed through week 48 and no new safety signals identified. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05881785 (Date: 21 May 2023).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patients’ disposition through week 48. The number of patients completing or not completing treatment periods is calculated with the initial number of patients who were randomized to that group
非 KM Figure
Fig. 2Fig. 2 Response rate (NRI) for ASAS20 ( a ), ASAS40 ( b ), and ASAS5/6 ( c ) in the estimand population through week 48. * p <0.001, ^ p <0.01, + p <0.05 vs. placebo. Missing values were handled using NRI. Data are presented as the proportion of patients achieving ASAS20 ( a ), ASAS40 ( b ), and ASAS5/6 ( c ) responses at each study visit through week 48 in the estimand population. Results are shown separately for patients receiving xeligekimab 100 mg, xeligekimab 200 mg, placebo-100 mg, and placebo-200 mg, illustrating treatment response trends over time. ASAS Assessment of SpondyloArthritis international Society, NRI Non-Responder Imputation
非 KM Figure